Lemocin Flurbiprofen (Flurbiprofen)

Flurbiprofen blocks the activity of cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, preventing the formation of prostaglandins that mediate inflammation, pain, and fever. By lowering prostaglandin levels at sites of tissue injury, it reduces the sensation of pain and the swelling response.

The specific dose of Lemocin Flurbiprofen is determined by the prescribing healthcare professional based on the patient’s condition, age, weight, and overall health status. Dosage instructions are provided on the prescription label and should be followed exactly as directed by the prescriber.

Safety of flurbiprofen in pregnancy or while breastfeeding has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider after a thorough risk assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Flurbiprofen shares the core anti‑inflammatory and analgesic mechanisms of other NSAIDs but is often noted for its relatively rapid onset of pain relief. Compared with ibuprofen or naproxen, flurbiprofen may provide stronger analgesia at equivalent doses, though individual response and tolerability can vary.

Lemocin Flurbiprofen should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

The medication is supplied as an oromucosal tablet that is placed in the mouth and allowed to dissolve. Patients should follow the prescriber’s instructions regarding timing relative to meals and avoid chewing or swallowing the tablet whole to ensure proper absorption.

Serious risks include gastrointestinal bleeding or ulceration, severe allergic reactions such as anaphylaxis, acute kidney injury, and cardiovascular events like heart attack or stroke. Patients should be monitored for signs of these conditions and seek immediate medical attention if they occur.

Individuals with a known hypersensitivity to flurbiprofen or any other NSAID, those with active gastrointestinal ulcers or bleeding, severe renal or hepatic impairment, and patients with uncontrolled cardiovascular disease should avoid using Lemocin Flurbiprofen unless specifically directed by a healthcare professional.